Ideaya Biosciences (IDYA) announced that the first patient has been enrolled in its Phase 1 clinical trial evaluating IDE892, an investigational MTA-cooperative PRMT5 inhibitor being developed for patients with MTAP-deleted solid tumors, including non-small cell lung cancer and pancreatic cancer. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics of IDE892 as a monotherapy agent and in combination with IDE397, Ideaya’s MAT2A inhibitor, in mid-2026. Dual inhibition of IDE892 and IDE397 has demonstrated durable and well-tolerated tumor regressions in preclinical MTAP-deleted tumor models, including in NSCLC.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Citi opens ‘upside 90-day catalyst watch’ on Ideaya Biosciences
- Ideaya Biosciences enrolls first patient in IDE034 trial
- IDEAYA Biosciences: Methodologically De-Risked OpTimUM-02 Readout and Strong Cash Runway Support Buy Rating
- Ideaya Biosciences appoints Theodora Ross as chief development officer
- IDEAYA Biosciences: Pipeline Progress and Late-Stage Clinical Expansion Support Reiterated Buy Rating